Protease inhibitors targeting coronavirus and filovirus entry

Antiviral Research

Volumn 116, Issue , 2015, Pages 76-84

  Zhou, Yanchen ^a,b   Vedantham, Punitha ^c   Lu, Kai ^a   Agudelo, Juliet ^a   Carrion, Ricardo ^d   Nunneley, Jerritt W ^d   Barnard, Dale ^e   Pöhlmann, Stefan ^f   McKerrow, James H ^b,g   Renslo, Adam R ^c   Simmons, Graham ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^e UTAH STATE UNIVERSITY   (United States)

^f GERMAN PRIMATE CENTER   (Germany)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cathepsin; Coronavirus; Filovirus; Vinylsulfones

Indexed keywords

(N [1 (BENZENESULFONYL) 5 PHENYLPENT 1 EN 3 YL] 2 [(4 METHYLPIPERAZINE 1 CARBONYL)AMINO] 3 PHENYLPROPANAMIDE); ANTIVIRUS AGENT; CAMOSTAT; CATHEPSIN; PROTEINASE INHIBITOR; SMDC 256160; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; DIPEPTIDE; GABEXATE; N-PIP-PHENYLALANINE-HOMOPHENYLALANINE-VINYL SULFONE PHENYL; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TMPRSS2 PROTEIN, HUMAN; VINYL DERIVATIVE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BUNDIBUGYO EBOLAVIRUS; CHAGAS DISEASE; CHRONIC PANCREATITIS; CONTROLLED STUDY; CORONAVIRUS; DRUG EFFECT; DRUG SYNTHESIS; DRUG TARGETING; EBOLA VIRUS; FEMALE; FILOVIRUS; HUMAN; HUMAN CELL; HUMAN CORONAVIRUS NL63; IN VIVO STUDY; LOW DRUG DOSE; MALE; MARBURG VIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESTON EBOLAVIRUS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SUDAN EBOLAVIRUS; TAI FOREST EBOLAVIRUS; VIRUS ENTRY; VIRUS VIRULENCE; ZAIRE EBOLAVIRUS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CORONAVIRIDAE; CORONAVIRUS INFECTIONS; DRUG EFFECTS; EBOLAVIRUS; FILOVIRIDAE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA; CORONAVIRUS; EBOLA VIRUS; MARBURGVIRUS; SARS CORONAVIRUS;

ANIMALS; ANTIVIRAL AGENTS; CATHEPSINS; CELL LINE, TUMOR; CORONAVIRUS; CORONAVIRUS INFECTIONS; DIPEPTIDES; EBOLAVIRUS; FILOVIRIDAE; GABEXATE; HUMANS; MICE; MICE, INBRED BALB C; PROTEASE INHIBITORS; SARS VIRUS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VINYL COMPOUNDS; VIRUS INTERNALIZATION;

EID: 84923219776     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.01.011     Document Type: Article

References (44)

1. M.H. Abdulla, K.C. Lim, M. Sajid, J.H. McKerrow, and C.R. Caffrey Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor PLoS Med. 4 2007 e14
2. K.K. Ang, J. Ratnam, J. Gut, J. Legac, and E. Hansell Mining a cathepsin inhibitor library for new antiparasitic drug leads PLoS Negl. Trop. Dis. 5 2011 e1023
3. S.C. Barr, K.L. Warner, B.G. Kornreic, J. Piscitelli, and A. Wolfe A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi Antimicrob. Agents Chemother. 49 2005 5160 5161
4. C. Beaulieu, E. Isabel, A. Fortier, F. Masse, and C. Mellon Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease Bioorg. Med. Chem. Lett. 20 2010 7444 7449
5. S. Bertram, I. Glowacka, M.A. Muller, H. Lavender, and K. Gnirss Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease J. Virol. 85 2011 13363 13372
6. S. Bertram, R. Dijkman, M. Habjan, A. Heurich, and S. Gierer TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium J. Virol. 87 2013 6150 6160
7. J.W. Choy, C. Bryant, C.M. CalvetS. Doyle, and S.S. Gunatilleke Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target Beilstein J. Org. Chem. 9 2013 15 25
8. R.I. Connor, B.K. Chen, S. Choe, and N.R. Landau Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes Virology 206 1995 935 944
9. C.W. Day, R. Baric, S.X. Cai, M. Frieman, and Y. Kumaki A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo Virology 395 2009 210 222
10. R.J. de Groot, S.C. Baker, R.S. Baric, C.S. Brown, and C. Drosten Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group J. Virol. 87 2013 7790 7792
11. S. Diederich, L. Thiel, and A. Maisner Role of endocytosis and cathepsin-mediated activation in Nipah virus entry Virology 375 2008 391 400
12. S. Diederich, L. Sauerhering, M. Weis, H. Altmeppen, and N. Schaschke Activation of the Nipah virus fusion protein in MDCK cells is mediated by cathepsin B within the endosome-recycling compartment J. Virol. 86 2012 3736 3745
13. J.C. EngelS. Doyle, I. Hsieh, and J.H. McKerrow Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection J. Exp. Med. 188 1998 725 734
14. S. Gierer, S. Bertram, F. Kaup, F. Wrensch, and A. Heurich The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies J. Virol. 87 2013 5502 5511
15. I. Glowacka, S. Bertram, M.A. Muller Allen, and E. Soilleux Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response J. Virol. 85 2011 4122 4134
16. K. Gnirss, A. Kuhl, C. Karsten, I. Glowacka, and S. Bertram Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression Virology 424 2012 3 10
17. H. Hofmann, G. Simmons, A.J. Rennekamp, C. Chaipan, and T. Gramberg Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors J. Virol. 80 2006 8639 8652
18. S. Ikeda, M. Manabe, T. Muramatsu, K. Takamori, and H. Ogawa Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate J. Am. Acad. Dermatol. 18 1988 1246 1252
19. W. Jacobsen, U. Christians, and L.Z. Benet In vitro evaluation of the disposition of a novel cysteine protease inhibitor Drug Metab. Dispos. 28 2000 1343 1351
20. P. Jaishankar, E. Hansell, D.M. ZhaoS. Doyle, and J.H. McKerrow Potency and selectivity of P2/P3-modified inhibitors of cysteine proteases from trypanosomes Bioorg. Med. Chem. Lett. 18 2008 624 628
21. M. Kawase, K. Shirato, L. van der Hoek, F. Taguchi, and S. Matsuyama Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry J. Virol. 86 2012 6537 6545
22. Y. Kumaki, M.K. Wandersee, A.J. Smith, Y. Zhou, and G. Simmons Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin Antiviral Res. 90 2011 22 32
23. Z.A. Memish, A.I. Zumla, R.F. Al-Hakeem, A.A. Al-Rabeeah, and G.M. Stephens Family cluster of Middle East respiratory syndrome coronavirus infections N. Engl. J. Med. 368 2013 2487 2494
24. J. Misasi, K. Chandran, J.Y. Yang, B. Considine, and C.M. Filone Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences J. Virol. 86 2012 3284 3292
25. M. Ndao, M. Nath-Chowdhury, M. Sajid, V. Marcus, and S.T. Mashiyama A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection Antimicrob. Agents Chemother. 57 2013 6063 6073
26. C.T. Pager, W.W. Craft Jr., J. Patch, and R.E. Dutch A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L Virology 346 2006 251 257
27. J.T. Palmer, D. Rasnick, J.L. Klaus, and D. Bromme Vinyl sulfones as mechanism-based cysteine protease inhibitors J. Med. Chem. 38 1995 3193 3196
28. J.T. Palmer, C. Bryant, D.X. Wang, D.E. Davis, and E.L. Setti Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K J. Med. Chem. 48 2005 7520 7534
29. J.T. Palmer, B.L. Hirschbein, H. Cheung, J. McCarter, and J.W. Janc Keto-1,3,4-oxadiazoles as cathepsin K inhibitors Bioorg. Med. Chem. Lett. 16 2006 2909 2914
30. R.M. Rydzewski, C. Bryant, R. Oballa, G. Wesolowski, and S.B. Rodan Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors Bioorg. Med. Chem. 10 2002 3277 3284
31. J.K. Sai, M. Suyama, Y. Kubokawa, Y. Matsumura, and K. Inami Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease J. Gastroenterol. 45 2010 335 341
32. B. Salvador, Y. Zhou, A. Michault, M.O. Muench, and G. Simmons Characterization of Chikungunya pseudotyped viruses: identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein Virology 393 2009 33 41
33. B. Salvador, N.R. Sexton, R. Carrion Jr., J. Nunneley, and J.L. Patterson Filoviruses utilize glycosaminoglycans for their attachment to target cells J. Virol. 87 2013 3295 3304
34. G. Simmons, R.J. Wool-Lewis, F. Baribaud, R.C. Netter, and P. Bates Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence J. Virol. 76 2002 2518 2528
35. G. Simmons, J.D. Reeves, A.J. Rennekamp, S.M. Amberg, and A.J. Piefer Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry Proc. Natl. Acad. Sci. U.S.A. 101 2004 4240 4245
36. G. Simmons, D.N. Gosalia, A.J. Rennekamp, J.D. Reeves, and S.L. Diamond Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry Proc. Natl. Acad. Sci. U.S.A. 102 2005 11876 11881
37. G. Simmons Zmora, S. Gierer, A. Heurich, and S. Pohlmann Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research Antiviral Res. 100 2013 605 614
38. I. Steffen, N.M. Liss, B.S. Schneider, J.N. Fair, and C.Y. Chiu Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses J. Virol. 87 2013 9558 9568
39. Fiopan® Tablets [package insert]. Ono Pharmaceutical Co., Ltd, Chuo-ku, Osaka, Japan; August 2009.
40. A.M. Zaki, S. van Boheemen, T.M. Bestebroer, A.D. Osterhaus, and R.A. Fouchier Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia N. Engl. J. Med. 367 2012 1814 1820
41. Y. Zhou, and G. Simmons Development of novel entry inhibitors targeting emerging viruses Expert Rev. Anti Infect. Ther. 10 2012 1129 1138
42. Y. Zhou, K. Lu, S. Pfefferle, S. Bertram, and I. Glowacka A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms J. Virol. 84 2010 8753 8764
43. Y. Zhou, J. Agudelo, K. Lu, D.H. Goetz, and E. Hansell Inhibitors of SARS-CoV entry-identification using an internally-controlled dual envelope pseudovirion assay Antiviral Res. 92 2011 187 194
44. Y. Zhou, I. Steffen, L. Montalvo, T.H. Lee, and R. Zemel Development and application of a high-throughput microneutralization assay: lack of xenotropic murine leukemia virus-related virus and/or murine leukemia virus detection in blood donors Transfusion 52 2012 332 342